Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slove-nian real-world data. Radiol Oncol [Internet]. 2026 Jul. 4 [cited 2026 Sep. 22];60(2):288-93. Available from: https://www.radioloncol.com/index.php/ro/article/view/4731